ArticleJournal of personalized medicine2016
An eMERGE Clinical Center at Partners Personalized Medicine.
Article in Journal of personalized medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics.Science translational medicine · 2020Pooled it
- Quantifying and improving rheumatoid arthritis algorithm performance in biobank settings.Seminars in arthritis and rheumatism · 2025Article
- High-throughput genetic clustering of type 2 diabetes loci reveals heterogeneous mechanistic pathways of metabolic disease.Diabetologia · 2023Article
- Article
- Article
- Article
- Article
- Integration of Biobanks in National eHealth Ecosystems Facilitating Long-Term Longitudinal Clinical-Omics Studies and Citizens' Engagement in Research Through eHealthBioR.Frontiers in digital health · 2021Article
- Genetic Loci and Physiologic Pathways Involved in Gestational Diabetes Mellitus Implicated Through Clustering.Diabetes · 2021Article
- Hematopoietic mosaic chromosomal alterations and risk for infection among 767,891 individuals without blood cancer.Research square · 2020Article
- Investigating the impact of disease and health record duration on the eMERGE algorithm for rheumatoid arthritis.Journal of the American Medical Informatics Association : JAMIA · 2020Article
- Article
- The use of electronic health records for psychiatric phenotyping and genomics.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics · 2018Review
- Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: A soft clustering analysis.PLoS medicine · 2018Article
- Advances in Sharing Multi-sourced Health Data on Decision Support Science 2016-2017.Yearbook of medical informatics · 2018Review
- Implementing Personalized Medicine in the Academic Health Center.Journal of personalized medicine · 2016Article
- Genomic sequencing in clinical practice: applications, challenges, and opportunities.Dialogues in clinical neuroscience · 2016Review
- Infrastructure for Personalized Medicine at Partners HealthCare.Journal of personalized medicine · 2016Article
- Precision Medicine: The new era in medicine.EBioMedicine · 2016Article
- Precision medicine and molecular imaging: new targeted approaches toward cancer therapeutic and diagnosis.American journal of nuclear medicine and molecular imaging · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The integration of electronic medical records (EMRs) and genomic research has become a major component of efforts to advance personalized and precision medicine. The Electronic Medical Records and Genomics (eMERGE) network, initiated in 2007, is an NIH-funded consortium devoted to genomic discovery and implementation research by leveraging biorepositories linked to EMRs. In its most recent phase, eMERGE III, the network is focused on facilitating implementation of genomic medicine by detecting and disclosing rare pathogenic variants in clinically relevant genes. Partners Personalized Medicine (PPM) is a center dedicated to translating personalized medicine into clinical practice within Partners HealthCare. One component of the PPM is the Partners Healthcare Biobank, a biorepository comprising broadly consented DNA samples linked to the Partners longitudinal EMR. In 2015, PPM joined the eMERGE Phase III network. Here we describe the elements of the eMERGE clinical center at PPM, including plans for genomic discovery using EMR phenotypes, evaluation of rare variant penetrance and pleiotropy, and a novel randomized trial of the impact of returning genetic results to patients and clinicians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.